Search
Braveheart Bio Ord Shs
BRVEAdd to Watchlist
18.000
0.000--
Close 09-22 16:00（ET）
--Market Cap
--P/E TTM
About Braveheart Bio Ord Shs Company
Braveheart Bio, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.
Braveheart Bio Ord Shs Profile
Ticker SymbolBRVE
Company nameBraveheart Bio, Inc.
IPO dateAug 06, 2026
CEOMurdoch (Travis)
Number of employees30
Security typeOrdinary Share
Fiscal year-endAug 06
AddressOne Letterman Drive, Building A
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94129
Phone14157076312
Websitehttps://www.braveheart.bio
Ticker SymbolBRVE
IPO dateAug 06, 2026
CEOMurdoch (Travis)
Company Executives of Braveheart Bio Ord Shs
Name
Name/Position
Position
Shareholding
Change
Relevant data have not been disclosed by the company yet.
Name
Name/Position
Position
Shareholding
Change
Relevant data have not been disclosed by the company yet.